approval · primary record
ARIPIPRAZOLE
4 approval events · latest 2026-07-31
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-07-31 |
| Approval events | 4 |
| Brand | MEZOFY |
| Sponsor | CMG PHARM CO LTD |
| Route | ORAL |
Approval history
4 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-07-31 | FDA | NDA | MEZOFY | CMG PHARM CO LTD | ORAL |
| 2025-03-28 | FDA | NDA | ABILIFY ASIMTUFII | OTSUKA | INTRAMUSCULAR |
| 2025-03-20 | FDA | NDA | OPIPZA | XIAMEN LP PHARM CO | ORAL |
| 2025-01-22 | FDA | NDA | ABILIFY | OTSUKA | ORAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:28:37.134Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:aripiprazole
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Aripiprazole · compound